Cellectis. everyone, morning, you, productive XXXX and for Good thus been Arthur. thank year us you, for joining a Thank has far today.
and and ASH oral myeloid we've AMELI-XX or fronts activity We're is was from UCARTXXX acute clinical refractory step relapsed patients. is announced Ontology's a safety, University data dose of leukemia. persistence these American lack expansion, at also with trial, for forward escalation progress to proud clinical today. leukemia Acute which preliminary study with We therapy huge accepted present in reinforces refractory Center UCARTXXX patients. Medical a CSX that data with evaluating share to Amsterdam patients patients the for expansion data preclinical dose presentation a to myeloma which Yesterday, Cellectis target share myeloid excited Society options. of the abstract all UCARTCSX, unmet Meeting. cell on We're medical of need And of make thrilled our we're at Annual sponsored made have great product will on the for relevant encouraging in an are the and multiple that the that progress as allogeneic you continues relapsed X our its CAR-T trial. candidate, enrolling validation
candidate, gene that be dosing will patients with CAR-T now significant our in investment of We barriers therapy believe and in health. We manufacturing our manufactured that with been a control provided This contribute product initiate processes. competitors XXXX GMP has fully the highlighting Cellectis, are over will bringing how -- and facilities our eliminating for UCARTXX have building in-house our some milestone the and facing. facing manufacturing could independence new company cell fully to
are times and Our our production goal safety provide lead sure and met is in consistency to adaptability. and
rapidly therapeutic not registration, our product having monitor promising leading we candidates Importantly, filing. responses, means we possible at the manufacturing can clinical in-house best to that optimize as
of Allogene's greatly cell product our allogeneic accomplishment broader paves share excitement CAR-T as B patient it for access was our a pipeline that ALLO-XXXA several to trial the II patients pivotal to quarter, lymphoma. as road We for disclosed large announced starting Allogene be highlight potentially exciting This continued Selectus, with to it both candidate for allogeneic our partnership the milestones. this Phase increase of cell and partners first for therapy.
TIL modified was the observation clinical period therapy. lymphocyte, for safety in the Iovance that announced dosed frenetically or Iovance partner, trial and IOV-GMX-XXX edited the licensed first Our patient completed tumor-infiltrating tailing
the treated metastatic advanced of For melanoma. cancer non-small previously and cell lung treatment
Frattini, core our editing Medical the been along partner With take the natural of that the Cellectis, induced as cell-derived such once you I'd the Chief Mark trials serving past ahead. more is our both cells and cell Senior efforts for data turn of of wide preclinical a clinical pluripotent over with Finally, know partners' like applications of gene partner in These technologies, of Science, November. Vice deliver that Society therapy that, of will tailing at Previously, gene-edited new as our this X place Mark our and and clinical innovation advance product our member to announced in showcase clinical on as it over as Officer. to give stem range Clinical of trials. Meeting appointed the we're an present years. senior Most Cancer's pipeline. killer will Annual order gene sponsor President overview that TALEN a choice Mark, Mark go newly our a has of team call and on achievements types will to of that Cytovia Immunotherapy please across cell promise preclinical to the continuing constant of he
